Introduction
Introduction
Membrane phospholipids are key cell components with both a primary structural role, forming the basis of cell membranes, and a regulatory role providing pools of intermediates for intracellular signal transduction. The most abundant structural phospholipid in eukaryote cells is was obtained from Fisher Scientific in 10X concentrated solution and diluted 10 fold with distilled water.
Tissue culture
The breast cancer cell lines BT474, MDA-MB-468 and SKBr 3 were obtained from the American Tissue Culture Collection (LGC Standards, Teddington UK) and maintained in Dulbecco's Modified Eagles medium supplemented with penicillin (10,000units/100ml)/Streptomycin (10,000μg/100ml) and 10% foetal bovine serum in a CO 2 incubator with humidified CO 2 :air (5%:95%) at 37°C.
[ 3 H-methy]Choline cellular incorporation
Cells were grown until confluent in 75cm 2 tissue culture flasks (Nunclon, Thermo Scientific UK) and seeded (1x10 6 cells per flask) into 25cm 2 flasks. After 24h cells the media was replaced with either fresh medium or fresh medium with metformin (4mM) [21] . The flasks were then incubated for 72h unless otherwise stated.
[ 3 H-methy]lcholine chloride uptake and phosphorylation: Media was replaced with 0.5ml of media containing [ 3 H-methyl]choline chloride (185KBq/ml) and incubated at 37°C for 15min then washed rapidly 4x with ice cold phosphate buffered saline (PBS). The cells were then detached with 0.3ml of a solution of 0.05% trypsin: EDTA (Gibco UK) and neutralised with 0.3ml of medium. The cells were centrifuged at 1000g for 5min at 4°C and the media removed and retained. The cells were fractionated into lipid and aqueous phases by resuspension in 0.25ml of methanol (MeOH): CHCl 3 (2:1) and placing on ice for 1h after which 0.125ml of CHCl 3 and 0.125ml of Tris buffer (10mM) were added. The phases were then separated by centrifuging at 10,000g for 5min. The aqueous (upper phase) was then collected and the lipid (lower phase) placed in a scintillation vial (Perkin Elmer UK) with 3ml of scintillation fluid (Ultima Gold, Perkin Elmer UK) mixed and the activity counted on a TRI-CARB 2100TR liquid scintillation counter (Perkin-Elmer UK). Phosphorylated and non-phosphorylated [ 3 Hmethyl] Choline in the aqueous phase and the retained media were then determined as described below.
Determination of Phosphorylated [ 3 H-methyl] Choline by precipitation
To determine the amount of phosphorylated [ 2 . The mixture was then repeatedly mixed on a vortex mixer for 5min then centrifuged at 10,000g for 2min to pellet the precipitated phosphates. The radioactivity in a 200ul sample of the supernatant (containing non-phosphorylated [ 3 Hmethyl] Choline) was determined and the difference between the two samples, after allowing for dilution, was the amount of phosphorylated radioactivity [30] .
Determination of rate of [ 3 H-methyl]choline incorporation into lipid
Cells were seeded into 25cm 2 flasks, treated with metformin (4mM) for 72h then pulsed with [ 3 H-methyl]choline as described for '[ 3 H-methy]lcholine chloride uptake and phosphorylation'. After washing with ice-cold PBS the cells were incubated for 0 and 1h with fresh 0.5ml of non-radioactive medium (chase) after which the media was collected and the cells washed 2x with 0.2ml PBS and the washes pooled with the medium. Radioactivity was counted in the pooled media/ washes. The cells were trypsinised and radioactivity in the cells was determined after fractionation into lipid and aqueous phases as described above.
Determination of [

C(U)]-glucose incorporation into lipids and glycerol
Cells were set up and treated as described for '[3H-methy]Choline cellular incorporation' except they were incubated with media containing [ 14 C(U)]glucose (185KBq/ml) for 2h then washed 5x with ice-cold PBS. The cells were detached by treatment with trypsin and after addition of medium, transferred to microfuge tubes and centrifuged at 400g for 5min. They were then washed 2x with ice-cold PBS and the washes and media pooled and radioactivity counted. The cells were then fractionated into lipid and aqueous fractions as described above ([   3   H methy]Choline cellular incorporation). The radioactivity in a 50ul sample of the lipid fraction was counted and the solvent from the remainder evaporated. The lipids were then subjected to saponification by addition of KOH (10M) in water: ethanol (1:10) and heating to 70°C for 20min [31] . The fatty acids and glycerol were then separated into lipid and aqueous fractions [32] and radioactivity counted in the aqueous phase (glycerol) and the lipid phase.
Thin layer chromatography (TLC)
Composition of lipid-phase: Lipid phase extracts were subject to TLC on aluminium backed silica-gel plates (Merck, Germany) using a mobile phase of chloroform/methanol/acetone/acetic acid/water (40:14:15:12:7 v/v) (modification of [33] . The plates were cut into 7mm pieces placed in scintillation vials. The silica gel was loosened by treatment with 0.1ml of NaOH (1M) and neutralised with HCl. After addition of scintillation fluid the bare aluminium pieces were removed and the samples counted. Standards consisting of pure phosphatidylcholine and lysophosphatidylcholine were run and visualised using iodine vapour. The two lipids appeared as streaks with R f values in the range 0.28-0.47 and 0.73-1.0 respectively. Separation of aqueous phase components: Aqueous phase extracts were separated on aluminium backed silica plates using a mobile phase consisting of 0.5% saline/methanol/NH 4 CTP:phosphocholine cytidylyltransferase (CCT) assay. Cells were treated and lysed as described. A 50μl sample of complete lysate was reserved and the remainder centrifuged at 20,000g for 15min at 4°C. The supernatant was discarded and the pellet (membrane fraction) was suspended in 100μl of homogenisation buffer. CCT activity was assayed in both the complete lysate (total activity) and the membrane fraction by addition of 20μl to 100μl of CCT reaction buffer consisting of 65mM Tris-Hcl pH7.5, 3mM CTP, 10mM MgCL 2 , 2mM EDTA, 45mM NaCl, 0.25mM phosphocholine and [
3 H] phosphocholine (37KBq) [37] . After vortex mixing the mixture was incubated in a water bath at 37°C for 1h. The reaction was then stopped by heating to 100°C for 2min. The product, [ 3 H] CDP-choline, was separated from
]-phosphocholine using TLC as described above for aqueous phase components. Nonradioactive CDP-choline was run on the outer lanes of the TLC plate and visualised using UV to guide removal of the silica from the enzyme assay samples. These were scraped into scintillation vials and [
3 H]CDP-choline determined using scintillation counting. Phosphatidylcholine specific Phospholipase C activity (PtdCho PLC). PtdCho-PLC activity was determined using a kit (Red phosphatidylcholine-specific phospholipase C assay kit, Amplex, Invitrogen Ltd Paisley UK) following the manufacturer's instructions.
Protein assay. Protein determination was carried out on all lysate preparations for normalisation of the enzyme assays using the bicinchoninic assay (Sigma-Aldrich, UK.
Cell cycle distribution
Cells were seeded in 25cm2 flasks and incubated at 37°C for 24h then treated with 4 mM metformin for 24, 48 or 72h then harvested by treatment trypsin and after addition of medium transferred to 1.5ml microfuge tubes. They were then centrifuged at 400g for 5min and the supernatant discarded. After two PBS washes they were re-suspended in 0.3ml PBS followed by fixation with 70% ice-cold ethanol during vortexing. The fixed cells were kept at -20°C prior to flow cytometry analysis. For the cell cycle analysis, fixed cells were adjusted to 5x10 5 cells/ml and washed 2 times with PBS supplemented with 1% albumin. Then the cells were centrifuged at 1000g for 5mins and resuspended in 1ml of staining buffer containing 50ug/ml propidium iodoide, 50ug/ml ribonuclease A, 0.1% v/v triton-x-100 in PBS and incubated for 15 min at room temperature. The stained nuclei were kept at 4°C and protected from light. Flow cytometry was performed using 488 nm laser light on a FACSCalibur flow cytometer (Becton Dickinson) and CELLQuest software (Becton Dickinson) equipped for fluorescence detection, forward, 90°angle light scatter and doublet discrimination. The data analysis was done with Flowjo cell cycling software.
Statistics
Statistical differences between means were determined using the student's t test. Tracer incorporation experiments were carried out at least three times with duplicate samples. Enzyme assay experiments were carried out 2 or more times with triplicate or more samples. ]choline into lipid in metformin-treated cells may be due to decreased rate of degradation or increased rate of synthesis of PtdCho or both. The formation of CDP-choline catalysed by CCT is the rate limiting step for PtdCho formation. Total CCT activity was increased in BT474 (t = 3.2, p<0.05) and MDA468 cells (t = 9.6, p<0.001) and membrane-associated CCT activity was increased in cell lines treated with metformin (BT474 (t = 5.6, p<0.02), MDA-MB-468 (t = 8, p<0.001), SKBr3 (t = 6.55, p<0.01)). The activity of the catabolic enzyme PtdCho-phospholipase C was significantly decreased (BT474 t = 3.22, p<0.05; MDA-MB-468 6.16, p<0.01; SKBr 3 t = 9.5, p<0.001) by treatment with metformin (results shown in Fig 3) for 72h.
CCT and PtdCho-PLC activity were also determined after 24h treatment of MDA-MB-468 cells with metformin. PtdCho-PLC activity was significantly (t = 15, p<0.001) decreased by a 24 h treatment with metformin (66 ± 3) compared with control cells (100 ± 1.3) but in contrast to the 72h treatment with metformin membrane CCT activity was not significantly (t = 0.8, not significant) changed (control: 100 ± 15; metformin treated for 24h: 108 ± 23).
The formation of PtdCho from CDP-choline requires diacylglycerol (DAG) which can be formed by several routes including the breakdown of PtdCho and other phospholipids by PLC, de novo synthesis from dihydroxyacetone phosphate and release from triacylglycerol by triglyceride lipase.
The lower level of PtdCho-PLC activity in the metformin-treated cells, compared with control cells, suggests that PtdCho-specific PLC activity isn't a source of increased DAG in metformin-treated cells. Further, treatment of MDA-MB-468 cells with the phosphatidylcholinephospholipase C inhibitor D609 (100μM) [27] actually resulted in more [ Fig 4) suggesting that PtdCho-PLC activity breaks down the newly formed PtdCho.
The effect of inhibition of de-novo synthesis of DAG was determined by treatment of control and metformin-treated MDA-MB-468 cells with the acetyl-CoA carboxylase inhibitor, TOFA (20μM) [29] for 4h and choline incorporation into the lipid fraction measured. Lipid PtdCho synthesis may vary through the cell cycle so control and metformin-treated MDA-MB-468 cells were subject to cell cycle analysis. Treatment with metformin for 48 (p = 10.8, t<0.001) and 72h (t = 12.7, p<0.001) but not 24h resulted in a significant increase in cells in G 0 /G 1 with a concomitant decrease in cells in S-phase after 48 (t = 13.7, p<0.001) and 72h (t = 13, p<0.001) metformin treatments compared with controls (Fig 7) .
Discussion
This study has demonstrated that treatment of breast cancer cells with metformin is associated with modifications in the activity of the enzymes choline kinase, CCT and PtdCho-PLC with corresponding changes in the incorporation of choline into Pcho and PtdCho. Metformin treatment was also found to be associated with modulated fatty acid and glycerol formation from glucose. These metformin associated changes are summarised in Fig 8. Metformin is currently undergoing clinical trials [38] for the treatment of cancer, however the mechanism of metformin's tumour growth inhibition is poorly understood [38] . Malignant transformation has been shown to be associated with increased cellular PCho [4] content which is attributed to increased choline kinase activity in breast cancer [6, 7] . Previous studies have shown that choline kinase [39] and phospholipase C activity [40] are important in cell survival and their inhibition results in decreased cancer cell proliferation. Decreased choline kinase and phospholipase C activities associated with metformin treatment, demonstrated in this study, may be amongst the mechanisms of tumour cell growth inhibition induced by metformin.
In agreement with previous studies [38] including studies of breast cancer cells [41] , treatment of cells with metformin was found to induce G 1 arrest in tumour cells which was The latter, which is derived from glyceraldehyde-3-phosphate during glycolysis, was increased corresponding with increased glucose utilisation by tumour cells treated with metformin [21, 43] . Increased glucose utilisation in breast cancer stem cells treated with metformin has been shown to be accompanied by increased lactic acid production [43] but decreased ATP synthesis. Zakikhani et al [44] have also shown that metformin treatment of MCF7 breast cancer cells increased glycolysis and concomitantly lactate production but decreased the concentration of tricarboxylic acid (TCA) cycle intermediates including citrate (TCA) which is a major source Cancer cells exhibit enhanced fatty acid synthesis which is essential for the production of complex lipids e.g. phospholipids for cell signalling and growth [45] . PtdCho-PLC degradation of PtdCho is a source of DAG [46] . Abalsamo et al [27] have shown that PtdCho PLC, but not PLD is increased in breast cancer cells compared with non-tumour cells and that inhibition of PLC by D609 induces cell cycle arrest. CCT is controlled by intracellular DAG level [47, 48] . Here PLC activity was found to be decreased by treatment of breast cancer cells with metformin however the increase in lipid produced from de novo synthesised glycerol may increase DAG content so increasing CCT activity. Alternatively, increased membrane CCT activity, which is evident at 72h but not 24h, may be a compensatory effect of decreased accumulation of choline by PtdCho observed at 24h but which then results in a higher rate of accumulation at later time points. This mechanism has previously been described for liver cells treated with the AMPK activator AICAR [49] . Houweling et al [49] observed that membrane CCT activity was increased in hepatocytes treated with AICAR though they did not report increased accumulation of choline by PtdCho. However as PtdCho accumulation is a net effect of anabolism and catabolism its accumulation may not always be evident in response to increased CCT activity.
Although de novo fatty acid synthesis is decreased by treatment with metformin, [ 3 H]choline accumulation into PtdCho is increased indicating that alternative sources of fatty acids must be utilised by breast cancer cells treated with metformin. Possible sources include those derived from the extracellular fluid and ones synthesised from acetate. Breast cancer cells have been shown to utilise fatty acids present in serum in the incubation medium [50] . Acetyl-CoA for de novo synthesis of fatty acids can be formed by the acetyl CoA synthase (ACSS) catalysed ligation of acetate with CoA [50] . A recent study has shown that exposure of breast cancer cells to hypoxia which, in common with metformin induces metabolic modifications by increased AMPK activity, exhibited enhanced fatty acid synthesis from acetate by increasing the expression of an isoform of ACSS. Schug el al [51] also demonstrated that hypoxia decreased the conversion of glucose to fatty acids whilst maintaining glycerol-3-phosphate production for lipid synthesis. In conclusion we have shown that treatment of breast cancer cells with metformin increases accumulation of choline by phospholipid, increases CCT activity and decreases choline kinase and PLC activity. We have also shown that the glycerol fraction derived from glucose is increased by breast cancer cells treated with metformin which may contribute to increased levels of DAG for PtdCho formation. We have also confirmed that the formation of glucosederived fatty acids is decreased in metformin treated cells. Techniques that measure phosphatidylcholine metabolism including 
